Panion & Bf Biotech Inc. · TWSE:1760

Panion & Bf Biotech — Q1 2026 Earnings Presentation

70 slides from Panion & Bf Biotech's earnings presentation, Jun 25, 2026

  1. Slide 1: Health, Sharing, and Care

    寶齡富錦生技 (1760.TT) Health, Sharing, and Care – Innovative healthcare solutions for a better life Copyright © PANION & BF BIOTECH INC.

  2. Slide 2: Disclaimer

    Panion & BF Biotech Inc. (The Company) Disclaimer  The presentation and the relevant information mentioned in this material, including operating performance, financial performance and the business outlook, have been compiled from both internal and external resources.  These forward looking stateme

  3. Slide 3: Panion & BF Biotech Inc.

    Panion & BF Biotech Inc. • Establishment：January 7, 1976 in Taipei Taiwan. • IPO Date：January 23, 2018 on Taiwan Stock Exchange Main Board (Ticker : 1760) • Integration Capability：Vertical Integration Converting R&D, Manufacturing, Branding, Channel Marketing, and Diversification. • Diversified Busi

  4. Slide 4: Content

    目錄 Content 營運成果 (Operation Highlights) 財務報告 (Financial Statements) • 永續發展報告 (Sustainability Development) 各事業體的發展 (Key Business Units and Outlook) Q&A

  5. Slide 5: Content

    目錄 Content 營運成果 (Operation Highlights) 財務報告 (Financial Statements) • 永續發展報告 (Sustainability Development) 各事業體的發展 (Key Business Units and Outlook) Q&A

  6. Slide 6: Financial Statements

    財務報告 Financial Statements 2026/06/25 Copyright © PANION & BF BIOTECH INC.

  7. Slide 7: Consolidated Financial Statement of Comprehensive Income 3-2026/1-3

    Consolidated Financial Statement of Comprehensive Income 2023-2026/1-3 2,500,000 2,000,000 1,500,000 1,000,000 500,000 0 L 2023 2024 2025 2026/1-3 Operating Revenue Gross profit lm Profit from continuing operations before tax @ Net income In Thousands of New Taiwan Dollars 2023 2024 2025 2026/1-3 (O

  8. Slide 8: Revenue from Major products

    900,000 ‘800,000 700,000 600,000 500,000 Revenue from Major products 2023-2026/1-3 _ vo _ . || ae __-_ Pharmaceutical retain Cosmeceutical —_ Sales royalty fees Diagnostic Other(Note) 2023 ™2024 2025 ™ 2026/1-3 In Thousands of New Taiwan Dollars products lines] Pharmaceutical | Supplement Cosmeceuti

  9. Slide 9: Consolidated Financial Statement of Comprehensive Income 2026/1-3 vs 2025/1-3

    Consolidated Financial Statement of Comprehensive Income conor 2026/1-3 VS. 2025/1-3 , oe —_ Operating Revenue Gross profit Profit from continuing operations Net income before tax m 2025/1-3(A) ™2026/1-3(B) In Thousands of New Taiwan Dollars 2026/1-3 2025/1-3(A) 2026/1-3(B) pee a BA) rate% Operating

  10. Slide 10: Revenue from Major products 2026/1-3 vs 2025/1-3

    Revenue from Major products 2026/1-3 VS. 2025/1-3 150,000 - | = fn | ; | ft | = - a _ Pharmaceutical Supplement Cosmeceutical Sales royalty fees Diagnostic Other (Note) m 2025/1-3(A) m 2026/1-3(B) In Thousands of New Taiwan Dollars products lines | Pharmaceutical] Supplement | Cosmeceutical |Sales r

  11. Slide 11: PBF Sustainability Development

    PBF Sustainability Development PBF ESG Date:2026/06/25 Copyright © PANION & BF BIOTECH INC. Copyright © PANION & BF BIOTECH INC.

  12. Slide 12: 2025 Greenhouse Gas (GHG) Inventory

    2025 Greenhouse Gas (GHG) Inventory Compliance Standard International Standard: ISO 14064-1: 2018 Organizational and Reporting Boundaries • Inventory Period: 2025/01/01 ~ 2025/12/31 • Operational Boundary: Operational Control Approach. A comprehensive inventory conducted across a total of 8 sites wi

  13. Slide 13: 2025 Sustainability Report

    2025 Sustainability Report Report Framework & Highlights • International Alignment Standards: Prepared in accordance with the GRI 2021 Core Standards and the SASB Healthcare (Biotechnology & Pharmaceuticals) Industry Classification. • Regulatory Compliance: Complies with the "Corporate Governance 3.

  14. Slide 14: IFRS Sustainability Disclosure Standards Integration & Implementation

    IFRS Sustainability Disclosure Standards Integration & Implementation • Phase 3 Implementation Enterprise: Listed companies with paid-in capital of less than NT$5 billion • Panion & BF Biotech, in collaboration with KPMG, drives the promotion and implementation of IFRS sustainability information. Th

  15. Slide 15: PBF Key Business Units and Outlook

    各事業體的發展 PBF Key Business Units and Outlook 2026/06/25 Copyright © PANION & BF BIOTECH INC. Copyright © PANION & BF BIOTECH INC.

  16. Slide 16: PBF Growth Architecture: Three Growth Pillars

    PBF Growth Architecture: Building on Our Foundation to Develop Three Growth Pillars Building on our generics and infection-control businesses, we continue to invest in R&D and capital, extending into three major growth engines: new drugs & APIs, diagnostics, and medical aesthetics Copyright © PANION

  17. Slide 17: From R&D Roadmap to Long-Term Value: Healthspan Strategy

    From R&D Roadmap to Long-Term Value: Advancing PBF's Healthspan Strategy 17

  18. Slide 18: From R&D Roadmap to Long-Term Value: Healthspan Strategy

    From R&D Roadmap to Long-Term Value: Advancing PBF's Healthspan Strategy 18

  19. Slide 19: Innovative Medicine

    創新醫療事業群 Innovative Medicine 莊瑞元 Raymond Chuang 2026 1H Copyright © PANION & BF BIOTECH INC.

  20. Slide 20: Nephxoil China Approval: Achievement & Key Breakthrough

    Nephxoil® China Approval: Achievement & Key Breakthrough 里程碑與關鍵突破 原預計於第三季度取得藥品上市許可，在多方整合加速下提前於4月底獲批， 在未額外執行中國ＰＤ患者臨床試驗的情況下，透過法規科學證據整合及監管機關持 使本新藥得參與2026年度國家醫保目錄(NRDL)申報作業，加速市場滲透與放量時程。 續溝通，成功取得涵蓋ＨＤ及ＰＤ患者之全適應症核准，近一步擴大市場機會。 NMPA approval was obtained ahead of schedule in April 2026 (originally anticipated

  21. Slide 21: China Market Potential

    China Market Potential 中國市場發展狀況 World largest dialysis population 潛在總透析人口估計為二至三百萬人 Source: Chinese National Renal Data System (CNRDS). 19th Conference on Critical Care Nephrology & Blood Purification,Chinese Society of Nephrology, 2025. 21

  22. Slide 22: Business Model Evolution

    Business Model Evolution Royalty based + Asia Pacific commercialization platform 22

  23. Slide 23: Ferric Citrate Japan

    Ferric Citrate Japan Japan Ferric Citrate Sales Riona® 250 tablets ¥9,000 ¥8,000 • 2025: 8,479 million Yen, YOY 4% ¥7,000 growth Sales in Million Yen ¥6,000 • 2026Q1: 1861 million yen, YOY 4.7% ¥5,000 growth ¥4,000 ¥3,000 • To date no generic drug application has ¥2,000 been approved for Riona Table

  24. Slide 24: Ferric Citrate USA

    Ferric Citrate USA US Ferric Citrate Sales Auryxia® 1000 Tablets $200,000 $180,000 • 2025 net sales achieved US$178M, due to $160,000 CMS bundled payment and qualified for Sales in thousand USD TDAPA $140,000 $120,000 • 2026Q1: US$36.2M, lower than 2025 due to price competition. $100,000 • In additi

  25. Slide 25: Asia Pacific Market Expansion

    Asia Pacific Market Expansion FEXENOL® Generation I 第1代 Generation II 第2代 ESRD Dialysis 末期腎病透析市場 CKD 3-5 慢性腎病市場 NEPHOXIL 500 mg capsules FEXENOL 1000 mg tablets • KOREA: >100,000 dialysis patients. • TAIWAN: 2.6 million CKD patients LG Chem 2026 maintains expansion 1) Late stage NDA review targeting

  26. Slide 26: New Drug Pipeline

    New Drug Pipeline 新藥開發進行中 Pre Clinical Phase I Phase II Phase III PBF-501 AR inhibitor for Acne • Acne, Androgen Receptor Inhibition 雄性素受體抑制之痤瘡治療新藥 505(b)(2) • Secured 8 Patents Across 7 Major Markets | 已取得台、美、中、歐等七國共八項專利 • Formulation optimization and IP development PBF-502 ED Tri-Combo • Patented

  27. Slide 27: From R&D Roadmap to Long-Term Value: Healthspan Strategy

    From R&D Roadmap to Long-Term Value: Advancing PBF's Healthspan Strategy 27

  28. Slide 28: Ken Chiang, Diagnostic Division

    江政儒 創新診斷事業處 Ken Chiang, Diagnostic Division

  29. Slide 29: IVD Development Status 2025~2027

    IVD開發進度 IVDDevelopment Status 2025~2027 開發 送件 核准 2025 2026 2027 2028 H1 H2 H1 H2 H1 H2 H1 H2 退伍軍人菌抗原快篩試劑 1 Legionella pneumophila Ag 困難梭菌抗原快篩試劑 2 Clostridioides difficile Ag 呼吸道三合一抗原快篩家用 3 Res 3 Flu AB & COVID Ag Self Test iFOB&HP抗原快篩試劑 4 FOB & HP Ag Adeno&Rota&Noro抗原快篩試劑 5 Adenovirus & Rotavirus &

  30. Slide 30: Global IVD Approval Status

    2025全球IVD許可證概況 Global Approval Status Canada 1 US 5 Taiwan 18 Guatemala 3 Thailand 1 Singapore 2

  31. Slide 31: Pathogens of various kinds

    呼吸道病原 Respiratory Pathogen  新型冠狀病毒 (Sars-Cov-2)  流感病毒(Influenza Virus)  呼吸道融合病毒(RSV) 其他病原Others  腺病毒(Adenovirus)  A型鏈球菌(GAS)  B型鏈球菌(GBS)  嗜肺性退伍軍人桿菌(L. pneumophila)  登革熱病毒(Dengue Virus)  肺炎鏈球菌(S. pneumoniae)  屈公病病毒(Chikungunya Virus)  肺炎黴漿菌(M. pneumoniae)  B型肝炎病毒(HBV)  人類間質肺炎病毒(hMPV)  C

  32. Slide 32: Signals in the blood

    癌症指標 全血細胞分析 Cancer Marker Complete Blood Count 發炎指標  RBC  WBC  PLT  CA125 Inflammation Marker  CA15-3  Hb  HCT  Neut%  Lymph%  MPV  PDW  前降鈣素(PCT)  CA199  MCV  Mono%  PCT  MCH  Eos%  C反應蛋白(CRP)  PSA  MCHC  Baso%  介白素6號(IL-6) Signals in the blood 心臟指標 血液生化檢驗 Cardiac Marker Bioc

  33. Slide 33: Shortage of healthcare providers

    2 AE SO be SRA Shortage of healthcare providers

  34. Slide 34: Decentralization

    APUIME Decentralization

  35. Slide 35: Point of Care Test, Self Test

    Ae aes an te Bi =a Point of Care Test Self Test = IN CARE CENTER HOME e rel 4x on) Ce] we mest Fh RR eat Clinics Senior Care Center Home-based Medical Care

  36. Slide 36: Diagnostic Delay

    aD lan WE + js A Fel Diagnostic Delay Duration of Comorbidities

  37. Slide 37: Disease Definition of Delay

    Definition of Typical Comorbidities/ Disease Magnitude of Delay Source If Diagnosis Is Delayed → Delay Complications Missed early Early pandemic (2020) avg 4–7 days; Symptom onset → ARDS; thrombosis; myocarditis; Long antivirals/anticoagulation → COVID-19 later shortened to 1–2 days with rapid Lance

  38. Slide 38: Streamline the workflow from diagnosis to medical decision

    Streamline the workflow from diagnosis to medical decision! tEFt tee reales Fs SRR AY RL

  39. Slide 39: Diagnostic technology platforms

    gPCRLFIALAMP Ewoo CLIA COLORIMETRY Optical Scattering Microfluidics ELISA Electrical impedance Multiplex CLOUD Hot Spot Analysis Ate ot

  40. Slide 40: NANA HT (prototype)

    NANA HT (prototype) Ip NANA Ystrip NANA . NANA S1 Ys! Res3 FUAB& COVO-D Cal Cl A = 3 stp] {FOB & H. pylori

  41. Slide 41: Self-Applied Blood Collection Device

    Self-Applied Caplin | Blood Collection Devieg For decentralized POCT sampling lt € in cal aie No venipuncture fe) required (any Saal) \ A News = ’ a ~ 0.5-1.5 mL 1 de es sample volume a e - Neu en fg Homes Mill PocTworkons mote cal | rel - Nee ee — ¢ ~~ « fo} a (@mnen) a Home Testing J, ~— = ‘ e a

  42. Slide 42: VSTRIP Respiratory Panel

    [ VSTRIP™ 5 IN 4 RESPIRATORY PANEL COVID-19 (NecaTive — RSV (necarive ao wom —— Adenovirus (wecarive ——_—_—_————

  43. Slide 43: Application Scenario

    i j (5 1 Application Scenario fe se Bh ee POC Medical Services $e Ft BS AD Strengthen Tiered Healthcare $2 Ft Bil 5S BS Expand Home-Based Healthcare $27 SB BD tt Enhance Healthcare Resilience i) tt AE Reduce Antibiotic Overuse ah 2) 5D Ee HEI Reduce Diagnostic Delays m JAE SHome Care | Residential C

  44. Slide 44: Clinic-Based POCT

    診所即時檢測 Clinic-Based POCT  上呼吸道檢測Respiratory Infection Testing  抗生素管理Antibiotic Stewardship 44

  45. Slide 45: Clinic-Based POCT

    Clinic-Based Point-of-Care Testing 診所即時檢測 Clinic-Based POCT  慢性病管理Chronic Disease Management

  46. Slide 46: Home-Based Care

    到宅醫療 Home-Based Care  到宅 POCT 檢測At-Home POCT  長照與高齡監測Elderly & Long-Term Care Monitoring  感染與急性症狀評估Infection & Acute Symptom Assessment

  47. Slide 47: Disaster Medicine & Humanitarian Aid

    災難醫療&人道救援 Disaster Medicine & Humanitarian Aid  現場快速分流On-site Rapid Triage  傳染病群聚監測Infectious Disease Cluster Monitoring  慢病與高風險追蹤Chronic Disease & High-Risk Follow-up

  48. Slide 48: Public Health Trend Analysis

    公衛趨勢分析 Public Health Trend Analysis  傳染病熱點監測Infectious Disease Hotspot Monitoring  區域風險預警Regional Risk Alerts  公衛決策與資源配置Decision-Making & Resource Allocation 48

  49. Slide 49: Public Health Trend Analysis

    公衛趨勢分析 Public Health Trend Analysis  傳染病熱點監測Infectious Disease Hotspot Monitoring  區域風險預警Regional Risk Alerts  公衛決策與資源配置Decision-Making & Resource Allocation 49

  50. Slide 50: Public Health Trend Analysis

    公衛趨勢分析 Public Health Trend Analysis  傳染病熱點監測Infectious Disease Hotspot Monitoring  區域風險預警Regional Risk Alerts  公衛決策與資源配置Decision-Making & Resource Allocation 50

  51. Slide 51: Home Testing & Health Monitoring

    居家檢測與健康監控 Home Testing & Health Monitoring  預防醫學與健康管理Preventive Medicine & Health Management  居家感染檢測Home Infection Testing  居家慢病追蹤Home Chronic Disease Monitoring  出院後追蹤Post-Discharge Follow-up

  52. Slide 52: Our Ecosystem

    OUR ECOSYSTEM 1. RAPID DETECTION POCT test kits High sensitivity Easy to use > POCT DIAGNOSTICS ECOSYSTEM From Rapid Detection to Data Intelligence, Empowering Health Everywhere. 2. POCT CONNECTIVITY POCT devices ‘Auto data capture Secure transmission i. 3. CLOUD PLATFORM Data upload & management Re

  53. Slide 53: Test Reagents, Instruments, Data Management

    檢驗試劑 檢驗儀器 數據管理 Test Instruments Data Management Reagents  病原檢測Pathogen Detection  疾病診斷Disease Diagnosis  生物標記檢測Biomarker Detection  療效評估Treatment Monitoring  細胞檢測Cell Detection  疾病預測Disease Prediction / Prognosis  健康管理Health Management  基層醫療單位Primary Care Facilities  醫學中心Medical Centers  家

  54. Slide 54: Diagnosis within min

    Diagnosis within 30 min 307A Sera

  55. Slide 55: Streamline the workflow from diagnosis to medical decision

    Streamline the workflow from diagnosis to medical decision! tEFt tee reales Fs SRR AY RL

  56. Slide 56: VstriO AGE

    VstriO AGE

  57. Slide 57: From R&D Roadmap to Long-Term Value: Healthspan Strategy

    From R&D Roadmap to Long-Term Value: Advancing PBF's Healthspan Strategy 57

  58. Slide 58: Advancing Steadily, Milestone by Milestone

    1760.TT Since Last IR Advancing Steadily, Milestone by Milestone ① Milestones delivered one by one CHG Bathing Cloth PLLA Microspheres 保媄妍 Smooth Thread Pingzhen Phase II Key clinical trial completed Regulatory submission 11/11 17/45cm Completed, in mass production Submission by end of 2026/7 Licens

  59. Slide 59: One Demographic Wave, Two Ends to Monetize

    1760.TT PBF 2026 First Investor Conference One Demographic Wave, Two Ends to Monetize PBF in a Super-Aged Society — Disease Prevention × Disease-Free Anti- Aging Infection Control 20.06% Disability & Bedridden · Long-Term Care · Hospital-Acquired Infection Share of population aged 65+ · Taiwan offic

  60. Slide 60: The Medical-Aesthetics & Anti-Aging Market

    1760.TT Anti-Aging Platform The Other End of the Same Wave — the Medical-Aesthetics & Anti-Aging Market Aging → rising anti-aging awareness, structural market growth Medical-Aesthetics & Anti- Aging End • Getting older → rising anti-aging awareness • PLLA, Exosome + PRP, Sculpting Threads, Microneed

  61. Slide 61: Organizing the Product Line by Depth

    1760.TT Depth-based Portfolio Organizing the Product Line by 'Depth' Surface anti-aging (non-invasive) → Mesoderm (regenerative) → Deep age-reversal (invasive) Surface · Microneedle Platform WSP whitening / anti-wrinkle microneedle, SMP hair- simulation (196 needles/cm²) Mesoderm · Regenerative Aest

  62. Slide 62: Deep Layer: PLLA Microspheres + Sculpting Thread

    1760.TT Deep Layer — Minimally Invasive Deep Layer: PLLA Microspheres + Integrally-Molded Sculpting Thread Technology Differentiation · Domestic Proprietary Patents 保媄妍® Integrally-Molded PLLA Microspheres (Dermal Filler) Sculpting Thread SEM image Microspheres imaged under electron microscope (Left

  63. Slide 63: Hero Product: Exosome + PRP and Multi-Molecular HA

    1760.TT Mid Layer — Regenerative Hero Product: Exosome + PRP and Multi-Molecular HA Mesoderm Regenerative Aesthetics · Exclusive Standardized Technology Exosome + PRP (PxoBang) Multi-Molecular HA (Pearl Glow) • Bioactivity-protection technology (Double Umbrella): currently the only one storable at r

  64. Slide 64: Surface Layer: Microneedle Platform

    1760.TT Surface Layer — Microneedle Surface Layer: Microneedle Platform, Modular Targeting Layer Advanced casting process · One Needle, Two Bodies – Stacked Dual-Microneedle Technology 196 needles/cm² High-density matrix, precision delivery | needle tip (targeting layer) + needle body (carrier layer

  65. Slide 65: Production & Capacity Expansion for the Anti-Aging Market

    1760.TT Production Backbone Production & Capacity Expansion for the Anti-Aging Market: the Capacity Backbone for Growth Pingzhen Plant Phase II in mass production with doubled capacity; Phase III under construction Phase II · Completed, in formal mass Phase III · Building permit / tender from produc

  66. Slide 66: From R&D Roadmap to Long-Term Value: Healthspan Strategy

    From R&D Roadmap to Long-Term Value: Advancing PBF's Healthspan Strategy 66

  67. Slide 67: Development of PBF's Infection-Control Market

    1760.TT Infection Control (Hospital & LTC) Development of PBF's Infection-Control Market: the Invisible Defense Line of an Aging Society 20.06% ~650 billion Super-aged society · end- Long-term-care industry size 2025 (estimated) Industry estimate · Innovative Care Share aged 65+ (Ministry of the Int

  68. Slide 68: CHG Technology Platform, Multiple Product Derivatives

    1760.TT CHG Technology Platform Core of PBF's Infection-Control Market: the CHG Technology Platform, Multiple Product Derivatives Same core ingredient, Chlorhexidine Gluconate 2%, derived across multiple scenarios CHG 2% Bathing Cloth Periodontal Gel Skin disinfection · Dental · Launched Flagship CH

  69. Slide 69: The Bathing-Cloth Market: Three Layers of Need

    1760.TT Market — 3 Layers of Need The Bathing-Cloth Market: Three Layers of Need Spreading layer by layer from professional hospital settings to the home In-Hospital Defense Line Hospital ① Pre-op ② Post-op ③ ICU emergency disinfection ~2.31 million surgical procedures per year (Ministry of Health a

  70. Slide 70: Q&A Thank you for your attention

    Q&A Thank you for your attention. ir@pbf.com.tw Panion & BF Biotech Inc.

Panion & BF Biotech — Q1 2026 Earnings Presentation on 6ix